Clinical Insights

BIOSENSORS • February 5, 2024

In this clinical study conducted among 404 subjects in Ghatkopar, Mumbai, India, Gazelle demonstrated 100% sensitivity and specificity for identifying β-Thal major/intermedia vs. healthy subjects as well as subjects with β-Thal major/intermedia vs. β-Thal trait. Additionally, Gazelle demonstrated 100% sensitivity and 98.3% specificity for identifying β-Thal trait vs. healthy subjects.

HELIYON • December 6, 2022

In this clinical study conducted among 441 subjects including 250 subjects from 0 to 3 days old, 15 subjects from 4 to 28 days old, and 176 subjects from 28 days to 6 months old in Korle Bu, Ghana, Gazelle-Multispectral demonstrated 100% sensitivity and specificity for identifying newborns with diseases vs. healthy subjects; and subjects with disease vs. subjects with sickle cell trait and Hb C trait; Additionally, Gazelle-Multispectral demonstrated 97.3% sensitivity and 96.6% specificity for identifying subjects with sickle cell trait and Hb C trait vs. healthy subjects.

FRONTIERS IN MEDICINE • December 10, 2021

In this study, Gazelle, a new point-of-care, microchip-electrophoresis based sickle diagnostic device was compared to conventional laboratory-based hemoglobin electrophoresis and HPLC. The sensitivity and specificity of the Gazelle is comparable to hemoglobin electrophoresis and HPLC and eliminates the need for a laboratory. Gazelle yielded an overall high accuracy (99.0%) compared to reference standard tests (HPLC and hemoglobin electrophoresis).

LAB ON A CHIP • October 21, 2021

[Presenting] the first point-of-care (POC) platform to perform both anemia detection and Hb variant identification, using a single paper-based electrophoresis test.

ANALYST • April 30, 2020

HemeChip is a versatile, mass-producible microchip electrophoresis platform technology that may address unmet needs in biology and medicine, when rapid, decentralized hemoglobin or protein analysis is needed.